Takeda Pharmaceutical Balance Sheet Health
Financial Health criteria checks 2/6
Takeda Pharmaceutical has a total shareholder equity of ¥7,274.0B and total debt of ¥4,843.8B, which brings its debt-to-equity ratio to 66.6%. Its total assets and total liabilities are ¥15,108.8B and ¥7,834.8B respectively. Takeda Pharmaceutical's EBIT is ¥364.1B making its interest coverage ratio 2.2. It has cash and short-term investments of ¥457.8B.
Key information
66.6%
Debt to equity ratio
JP¥4.84t
Debt
| Interest coverage ratio | 2.2x |
| Cash | JP¥457.80b |
| Equity | JP¥7.27t |
| Total liabilities | JP¥7.83t |
| Total assets | JP¥15.11t |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: TKDA's short term assets (¥2,558.6B) exceed its short term liabilities (¥2,313.1B).
Long Term Liabilities: TKDA's short term assets (¥2,558.6B) do not cover its long term liabilities (¥5,521.7B).
Debt to Equity History and Analysis
Debt Level: TKDA's net debt to equity ratio (60.3%) is considered high.
Reducing Debt: TKDA's debt to equity ratio has reduced from 110.9% to 66.6% over the past 5 years.
Debt Coverage: TKDA's debt is not well covered by operating cash flow (14.8%).
Interest Coverage: TKDA's interest payments on its debt are not well covered by EBIT (2.2x coverage).